title: Contribution of whole-body 18FDG PET imaging in the management of cervical cancer.
abstract: OBJECTIVE
  The objective of this study was to assess the contribution of [(18)F]fluoro-2-deoxy-D-glucose positron emission tomography ((18)FDG PET) imaging in the management of cervical cancer.
  
  
  METHODS
  Fully corrected whole-body PET was performed in 60 patients (pts) with proven cervical cancer. In pretreatment staging, 22 pts underwent PET in addition to routine protocol including International Federation of Obstetrics and Gynecology (FIGO) staging and pelvic magnetic resonance imaging (MRI). Eighteen of them had pelvic lymphadenectomy. After treatment, PET was performed in 38 pts routinely followed up by clinical and radiological examinations. Results of PET and routine protocols were compared to final diagnoses, including histological findings in 31 pts and clinical outcomes in the other cases. Median follow-up time was 12 +/- 7.3 months.
  
  
  RESULTS
  In all but 2 patients (FIGO stage IA), both PET and MRI detected the primary tumor. In 6 pts, MRI alone noted loco-regional tumor spread but PET localized 9 unsuspected extrapelvic nodal sites (6 para-aortic, 2 mediastinal, and 1 supra-clavicular). However, PET missed 8 microscopic pelvic nodal metastases. In 18% of the patients, PET staging significantly influenced the treatment choices. In follow-up, PET accurately diagnosed a recurrent disease in 13 pts with falsely negative or equivocal conventional imaging (CI). Ten patients with a negative PET were still in complete remission after a minimal follow-up time of 12 months. Overall, the agreement of PET with final diagnosis was significantly better than that of routine protocol (P < 0.05).
  
  
  CONCLUSIONS
  Whole-body (18)FDG PET appears useful in the management of cervical cancer, in particular for staging extrapelvic metastases or optimally detecting a recurrence. MRI is better indicated for evaluating the loco-regional status of the disease.
authors.affiliation: Department of Nuclear Medicine, University Hospital of Liège, Sart Tilman-Bâtiment 35, 4000 Liège, Belgium. tarik.bel@swing.be
authors.forename: Tarik
authors.initials: T
authors.lastname: Belhocine
authors.forename: Alain
authors.initials: A
authors.lastname: Thille
authors.forename: Viviana
authors.initials: V
authors.lastname: Fridman
authors.forename: Adelin
authors.initials: A
authors.lastname: Albert
authors.forename: Laurence
authors.initials: L
authors.lastname: Seidel
authors.forename: Philippe
authors.initials: P
authors.lastname: Nickers
authors.forename: Frederic
authors.initials: F
authors.lastname: Kridelka
authors.forename: Pierre
authors.initials: P
authors.lastname: Rigo
mesh_terms: D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology / Q000601:surgery; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D014055:Tomography, Emission-Computed; D002583:Uterine Cervical Neoplasms / Q000000981:diagnostic imaging* / Q000601:surgery
chemical_list: D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18